Wellgistics Health Provides 2026 Corporate Outlook Integration of prescription drug dispensing optimization aritifical intelligence platform EinsteinRx into pharmacy client point-of-sales systems has commenced EinsteinRx

Health Provides 2026 Corporate Outlook

FL, January 7, 2026 - Wellgistics Health, Inc. ("Wellgistics") (NASDAQ: WGRX), a health information technology leader,

integrating proprietary pharmacy dispensing optimization artificial intelligence ( AI') platform EinsteinRx

into its patented blockchain-enabled smart contracts platform PharmacyChain , today provided a corporate outlook for 2026

months following my return to the role of President at Wellgistics, the Company now has a clear direction as we begin a hyper-focused

operational execution phase," said Prashant Patel, RPh, President & Interim-CEO of Wellgistics Health. "In 2026 we will

focus squarely on the implementation of our EinsteinRx AI platform into pharmacy client point of sale systems, onboarding and

increasing the percentage of our existing 6,500+ independent pharmacy customers that convert into our official Wellgistics pharmacy network

(the Wellgistics Pharmacy Network'). The key benefit for pharmacies enrolling in the Wellgistics Pharmacy Network will be

the integration of patient-specific health information pulled from authorized provider databases with just-in-time' prescription

optimization tools to empower our network's pharmacists to educate both providers and patients on the best personalized prescription

drug selection and prescription drug-adjacent products & services that are associated with the best patient outcomes. We have already

started the Wellgistics Pharmacy Network integration process with our closest pharmacy customers and are currently optimizing the onboarding

process to make it as seamless as possible for pharmacists, leveraging client feedback to improve speed of deployment and reduce process

friction. Once sufficiently optimized, we intend to accelerate the pharmacy conversion marketing effort as we also look to expand our

prescription drug manufacturer supplier relationships. We have set a goal of reaching a Wellgistics Pharmacy Network onboarding rate

of up to 500 pharmacies per month by year end 2026."

Patel continued, "While SGLT-2 drug Brenzavvy for the diabetes market is the first product that we are focused on optimizing

EinsteinRx for, we intend to quickly expand our branded manufacturer relationships to include other products that primarily target similar

patient populations that make up a significant proportion of the patients Wellgistics Pharmacy Network pharmacies serve, including patients

who have been prescribed GLP-1 agonist drugs and other drugs associated with cardiometabolic disease, such as Long COVID."

US diabetes market was estimated to be $48 billion in 2024, growing to $79 billions by 2031 according to iData Research. The North American

GLP-1 agonist market was estimated to be $53 billion in 2025, respected to grow to $156 billion by 2030 according to Grandview Research.

The US cardiometabolic disorders market was estimated to be $46 billion in 2024, expected to grow to $85 billion by 2031 according to

Mobility Forsights. Over 18 million patients in the United States lose an annual average of over $9,000 per patient, resulting in total

lost wages estimated at over $170 billion annually according to research published in Nature Publication Journals Primary Care Respiratory

with this onboarding optimization effort, our technology team has been working to complete its assessment of the resources required to

establish PharmacyChain," added Mr. Patel. "We will very soon provide updates on this exciting effort that we expect will

dramatically improve efficiency in the healthcare delivery market. PharmacyChain is being developed to implement end-to-end smart contracts

to drastically reduce the administrative burden associated with optimal healthcare delivery, improve payer transparency and significantly

increase the rate of timely insurance reimbursements for pharmacies, providers and other stakeholders in the United States while simultaneously

rooting out fraud, waste and abuse in the healthcare system."

Wellgistics Health, Inc.

Health (NASDAQ: WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial

intelligence platform EinsteinRx into its patented blockchain-enabled smart contracts platform PharmacyChain to optimize

the prescription drug dispending journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network")

and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub

services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access.

Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for

independent pharmacies.

more information, visit www.wellgisticshealth.com.

press release contains forward-looking statements within the meaning of the federal securities laws, including, without limitation, statements

regarding the parties' plans to negotiate definitive agreements, potential implementation, adoption, performance, revenue sharing,

and other anticipated benefits of the contemplated collaboration. These statements are subject to risks and uncertainties that could

cause actual results to differ materially, including those described in DataVault AI, Inc.'s and Wellgistics Health, Inc.'s

filings with the SEC. Forward-looking statements speak only as of the date hereof, and neither company undertakes any obligation to update

them except as required by law. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at www.sec.gov.

press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction, and there

shall be no sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Media & Investor Contact